[Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum (CDDP) as single agent or cddp in combination with adriamycin (ADM)].
Twenty-five patients with advanced ovarian cancer were treated with Cis-dichlorodiammneplatinum (CD-DP) 50 mg/m2 as single agent or CDDP 50 mg/m2 in combination with adriamycin (ADM) 50 mg/m2. Both CDDP and CDDP-ADM combination were administered intravenously. Thirteen patients received CDDP alone and twelve patients received CDDP-ADM combination. The single agent activity of CDDP produced a complete response (CR) of 23.1% and a partial response of 15.4% with an overall response rate of 38.5%. The combination of CDDP and ADM gave a response of 58.3% (CR 25.0%, PR 33.3%). Thus, the combination of CDDP and ADM produced a response rate superior to that of CDDP alone. These clinical findings were supported by our investigation of novel experimental therapies in 7, 12 dimethylbenz (a) anthracene induced rat ovarian cancer.